Managing IP Recognizes Robins Kaplan For Patent Contentious and PTAB Litigation in 2022

Robins Kaplan LLP is pleased to announce that it was named a “Highly Recommended Firm” for patent contentious litigation in Minnesota by Managing Intellectual Property, a recognition shared with just two other firms in the state. The magazine also recognized the firm for PTAB litigation, nationally.

According to Managing IP, firm rankings are based on a weighted system of peer and client feedback, combined with submissions analysis and independent research. For this year’s rankings, Managing IP considered key results that the firm obtained on behalf of clients between the fall of 2020 and 2021. Select patent litigation highlights included:

• Endonovo Therapeutics, Inc. v. Orthocore Medical, Inc.: Robins Kaplan LLP served as lead defense counsel representing Orthocore Medical, Inc., and its corporate parent Caerus Corporation in a patent infringement suit related to pulse electromagnetic field (PEMF) medical and veterinary devices. In December 2020, through aggressive representation, we secured a complete dismissal with prejudice of all claims asserted against our clients, without any settlement payment or other concessions.

• Collegium Pharmaceutical Inc. v. Teva Pharmaceuticals USA: In September 2020, on behalf of its client Collegium, Robins Kaplan brought to resolution a significant patent litigation against Teva related to Xtampza® ER, Collegium’s brand abuse-deterrent oxycodone with annual sales in excess of $100 million. Under the settlement, Teva agreed to a consent judgment confirming that its proposed generic products infringe Collegium’s 14 asserted Orange Book-listed patents. Collegium also agreed to grant Teva a license to market its generic version of Xtampza® ER in the United States beginning on or after September 2, 2033.

• TQ Delta, LLC v. 2Wire: In May 2019 and January 2020, on behalf of its client TQ Delta, Robins Kaplan, as conflicts counsel conducting the investigation and trial presentation of Broadcom semiconductor chipsets, achieved jury verdicts in favor of TQ Delta that defendant 2Wire, Inc. infringed two sets of patents relating to Digital Subscriber Line (DSL) patents, and that the patents were not invalid. Further liability trials are schedule for 2022. This is part of a series of related lawsuits against multiple defendants in which TQ Delta has asserted ten sets of patents from its DSL patent portfolio, which is the industry’s largest, comprising 29 patent families, 70 United States patents, 140 additional patents in other countries, and 65 patents pending worldwide.

“We are thrilled that Managing IP continues to recognize Robins Kaplan’s unique ability to take complex patent cases to the mat in both federal court and before the PTAB,” said Christopher Larus, Chair of the National IP and Technology Litigation Group.